Stuart Chaussee & Associates, Inc. Bei Gene, Ltd. Transaction History
Stuart Chaussee & Associates, Inc.
- $184 Million
- Q1 2024
Shares
2 transactions
Others Institutions Holding BGNE
# of Institutions
214Shares Held
45.1MCall Options Held
76.5KPut Options Held
72.3K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.64 Billion20.93% of portfolio
-
Capital International Investors Los Angeles, CA7.06MShares$1.09 Billion0.23% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$801 Million17.98% of portfolio
-
Primecap Management CO Pasadena, CA5MShares$774 Million0.59% of portfolio
-
Baillie Gifford & CO3.73MShares$577 Million0.46% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $16B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...